BioSpace News Archive

The Therapeutic Antibody Revolution in the Post Genomics Era: Using High Throughput SPR to Explore the Full Kinetic and Epitope Diversity of Antibody Libraries Supporting mAb, CAR-T, Bispecifics and ADC Therapeutic Discovery

Esperion announced the completion of patient enrollment in the CLEAR Cardiovascular Outcomes Trial.

The data monitoring committee recommended the trial continue as planned, with an estimated primary completion date in February 2022.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Orchard Therapeutics announced results from an integrated data analysis of OTL-200, a gene therapy in development for the treatment of metachromatic leukodystrophy (MLD) at the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy.

100% Single-Dose Protection Observed in Lethal Challenge Model

The Centers for Disease Control and Prevention announced the recipients of its Overdose Data to Action grants, including those in 17 local jurisdictions.

Evonik Venture Capital has invested in a 3D-printing start-up in China that makes implants for neuro and spine surgery.

Theragnostics announces a licence agreement with AstraZeneca for intellectual property (IP) that enables Theragnostics’ freedom to operate globally in the diagnostic field of certain selected radionuclide-labelled PARPi Polymerase inhibitors) with an option to an exclusive licence for freedom to operate globally in the therapeutic field of certain selected radionuclide-labelled PARPi.

TreeFrog Therapeutics, an expert stem cell company, announces that it has received close to €3M in non-dilutive funding from French and European programs.